134 related articles for article (PubMed ID: 11342329)
1. The use of cytotoxic t cells for the prevention and treatment of epstein-barr virus induced lymphoma in transplant recipients.
Savoldo B; Heslop HE; Rooney CM
Leuk Lymphoma; 2000 Nov; 39(5-6):455-64. PubMed ID: 11342329
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.
Liu Z; Savoldo B; Huls H; Lopez T; Gee A; Wilson J; Brenner MK; Heslop HE; Rooney CM
Recent Results Cancer Res; 2002; 159():123-33. PubMed ID: 11785836
[TBL] [Abstract][Full Text] [Related]
3. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.
Sun Q; Burton R; Reddy V; Lucas KG
Br J Haematol; 2002 Sep; 118(3):799-808. PubMed ID: 12181048
[TBL] [Abstract][Full Text] [Related]
4. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.
Davis JE; Moss DJ
Tissue Antigens; 2004 Apr; 63(4):285-92. PubMed ID: 15009802
[TBL] [Abstract][Full Text] [Related]
5. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.
Khanna R; Bell S; Sherritt M; Galbraith A; Burrows SR; Rafter L; Clarke B; Slaughter R; Falk MC; Douglass J; Williams T; Elliott SL; Moss DJ
Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10391-6. PubMed ID: 10468618
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.
Gustafsson A; Levitsky V; Zou JZ; Frisan T; Dalianis T; Ljungman P; Ringden O; Winiarski J; Ernberg I; Masucci MG
Blood; 2000 Feb; 95(3):807-14. PubMed ID: 10648390
[TBL] [Abstract][Full Text] [Related]
7. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients.
Savoldo B; Goss J; Liu Z; Huls MH; Doster S; Gee AP; Brenner MK; Heslop HE; Rooney CM
Transplantation; 2001 Sep; 72(6):1078-86. PubMed ID: 11579304
[TBL] [Abstract][Full Text] [Related]
8. Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes.
Emanuel DJ; Lucas KG; Mallory GB; Edwards-Brown MK; Pollok KE; Conrad PD; Robertson KA; Smith FO
Transplantation; 1997 Jun; 63(11):1691-4. PubMed ID: 9197369
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.
Heslop HE; Slobod KS; Pule MA; Hale GA; Rousseau A; Smith CA; Bollard CM; Liu H; Wu MF; Rochester RJ; Amrolia PJ; Hurwitz JL; Brenner MK; Rooney CM
Blood; 2010 Feb; 115(5):925-35. PubMed ID: 19880495
[TBL] [Abstract][Full Text] [Related]
10. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation.
Lucas KG; Small TN; Heller G; Dupont B; O'Reilly RJ
Blood; 1996 Mar; 87(6):2594-603. PubMed ID: 8630428
[TBL] [Abstract][Full Text] [Related]
11. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy.
Sherritt MA; Bharadwaj M; Burrows JM; Morrison LE; Elliott SL; Davis JE; Kear LM; Slaughter RE; Bell SC; Galbraith AJ; Khanna R; Moss DJ
Transplantation; 2003 May; 75(9):1556-60. PubMed ID: 12792514
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant.
Regn S; Raffegerst S; Chen X; Schendel D; Kolb HJ; Roskrow M
Bone Marrow Transplant; 2001 Jan; 27(1):53-64. PubMed ID: 11244438
[TBL] [Abstract][Full Text] [Related]
13. Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant.
Heslop HE; Perez M; Benaim E; Rochester R; Brenner MK; Rooney CM
J Clin Apher; 1999; 14(3):154-6. PubMed ID: 10540372
[TBL] [Abstract][Full Text] [Related]
14. Generation of EBV-specific CTLs suitable for adoptive immunotherapy of EBV-associated lymphoproliferative disease following allogeneic transplantation.
Hoffmann T; Russell C; Vindelov L
APMIS; 2002 Feb; 110(2):148-57. PubMed ID: 12064870
[TBL] [Abstract][Full Text] [Related]
15. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication.
Comoli P; Labirio M; Basso S; Baldanti F; Grossi P; Furione M; ViganĂ² M; Fiocchi R; Rossi G; Ginevri F; Gridelli B; Moretta A; Montagna D; Locatelli F; Gerna G; Maccario R
Blood; 2002 Apr; 99(7):2592-8. PubMed ID: 11895798
[TBL] [Abstract][Full Text] [Related]
16. A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation.
Uhlin M; Okas M; Gertow J; Uzunel M; Brismar TB; Mattsson J
Cancer Immunol Immunother; 2010 Mar; 59(3):473-7. PubMed ID: 19908041
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells improve the generation of Epstein-Barr virus-specific cytotoxic T lymphocytes for the treatment of posttransplantation lymphoma.
Wheatley GH; McKinnon KP; Iacobucci M; Mahon S; Gelber C; Lyerly HK
Surgery; 1998 Aug; 124(2):171-6. PubMed ID: 9706135
[TBL] [Abstract][Full Text] [Related]
18. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.
Doubrovina E; Oflaz-Sozmen B; Prockop SE; Kernan NA; Abramson S; Teruya-Feldstein J; Hedvat C; Chou JF; Heller G; Barker JN; Boulad F; Castro-Malaspina H; George D; Jakubowski A; Koehne G; Papadopoulos EB; Scaradavou A; Small TN; Khalaf R; Young JW; O'Reilly RJ
Blood; 2012 Mar; 119(11):2644-56. PubMed ID: 22138512
[TBL] [Abstract][Full Text] [Related]
19. Virus-specific cytotoxic T lymphocytes as prophylaxis for Epstein-Barr virus lymphoproliferative disease in pediatric bone marrow transplant recipients.
Norville R; Nance D; Cheshire S
J Pediatr Oncol Nurs; 1997 Oct; 14(4):194-201. PubMed ID: 9322393
[TBL] [Abstract][Full Text] [Related]
20. In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation.
Bollard CM; Gottschalk S; Huls MH; Molldrem J; Przepiorka D; Rooney CM; Heslop HE
Leuk Lymphoma; 2006 May; 47(5):837-42. PubMed ID: 16753867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]